KOKwabena Ofori-Kwakye

Kwabena Ofori-Kwakye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kwabena Ofori-Kwakye has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of the Safety Profile of Purified Pentadesma butyracea (Clusiaceae) Gum Intended as a Pharmaceutical Excipient

    by Mary-Ann Archer, Kwabena Ofori-Kwakye, Raphael Johnson, Ernest Amponsah Asiamah, Wisdom Ahlidja, Mustapha Abubakar Ahmed, Isaac Tabiri Henneh

    Pentadesma butyracea (family Clusiaceae ) bark is widely used in traditional medicine across sub‐Saharan Africa. However, the investigation of the safety profile of the gum exudate obtained from the stem bark of the plant is undocumented. This study evaluated the acute and subacute toxicity of the purified Pentadesma butyracea gum (PBG) in 36 male Sprague Dawley rats (8–10 weeks old; 100–182.08 g) to determine its safety profile for potential use as a pharmaceutical excipient. Acute toxicity was assessed using a single oral dose of 2000 mg/kg PBG, while subacute toxicity involved daily administration of 250, 500, and 1000 mg/kg PBG for 28 days. In the acute toxicity study, no mortality or significant adverse effects on behavior, body weight, relative organ weight, or histological features were observed, suggesting an LD 50 greater than 2000 mg/kg PBG. Hematological and biochemical analyses revealed no harmful deviations, supporting the safety of PBG in acute exposure. In the subacute study, no mortality occurred across all doses, and body weight changes were minimal. Relative organ weights of the kidneys, heart, and lungs increased at higher doses, indicating potential dose‐dependent effects. Biochemical analyses revealed no significant alterations in liver enzymes (AST, ALT, and ALP) or markers of kidney function (urea and creatinine) at lower doses; however, slight elevations in bilirubin and creatinine were observed at 1000 mg/kg PBG, suggesting mild hepatic and renal stress. Histopathological analysis confirmed the absence of severe pathological changes, with only mild and reversible alterations at higher doses. Overall, PBG demonstrated a favorable safety profile at doses below 1000 mg/kg, supporting its potential use as a pharmaceutical excipient. The preliminary phytochemical screening also showed the presence of tannins, glycosides, coumarins, sterols, and triterpenoids. Further studies, including chronic toxicity and pharmacokinetic assessments, are recommended to establish the long‐term safety of PBG.

  • Open Access

    Investigating the Presence of Falsified and Poor-Quality Fixed-Dose Combination Artemether-Lumefantrine Pharmaceutical Dosage Forms in Kumasi, Ghana

    by Simon Nyarko, Kwabena Ofori-Kwakye, Raphael Johnson, Noble Kuntworbe, Denis Dekugmen Yar

    Artemether-lumefantrine (AL) is a highly effective and commonly used Artemisinin-based Combination Therapy (ACT) for treating uncomplicated malaria caused by Plasmodium falciparum, including drug-resistant strains. However, ineffective regulatory systems in resource-limited settings can lead to the infiltration of poor-quality and counterfeit antimalarial medicines into the pharmaceutical supply chain, causing treatment failures, prolonged illness, and disease progression. The objective of the study was to assess the quality of selected brands of fixed-dose combination (FDC) AL tablets and suspensions marketed in Kumasi, Ghana. A total of fourteen brands of FDC AL medicines, comprising eight tablets and six suspensions were purchased from various retail pharmacy outlets in Kumasi, Ghana. All samples were subjected to thorough visual inspection as a quick means of checking quality through meticulous observation of the packaging or dosage form. The quality parameters of the tablets were determined using uniformity of weight, hardness, friability, and disintegration tests. Suspensions were assessed based on pH and compared with the British Pharmacopeia (BP) standard. The samples were then analyzed for drug content (assay) using reverse-phase high-performance liquid chromatography (RP-HPLC). All the tablet samples conformed to BP specification limits for uniformity of weight (deviation of less than5), hardness (4.010kg/mm2), friability (<1), and disintegration time (<15minutes). The active pharmaceutical ingredients quantitative assay demonstrated that all the tablets met the BP specifications (90110). The results of the pH studies showed that out of the six brands of suspension investigated, five (83.3) were compliant with the official specification for pH, while one (16.7) failed the requirement. Unlike the tablet brands, drug content analysis of the six suspensions showed that two (33.3) were substandard. The artemether and lumefantrine contents in these failed suspensions were variable (artemether: 81.31116.76; lumefantrine: 80.3599.71). The study results indicate that most of the tested products met the required quality standards, demonstrating satisfactory drug content and other quality specifications. The presence of substandard drugs underscores the necessity for robust pharmacovigilance and surveillance systems to eliminate counterfeit and substandard drugs from the Ghanaian market.


  • Open Access

    Development of the RP-HPLC Method for Simultaneous Determination and Quantification of Artemether and Lumefantrine in Fixed-Dose Combination Pharmaceutical Dosage Forms

    by Simon Nyarko, Kwabena Ofori-Kwakye, Raphael Johnson, Noble Kuntworbe, Desmond Asamoah Bruce Otu, Denis Dekugmen Yar, Yaa Asantewaa Osei

    Developing countries face enormous challenges with substandard and falsified antimalarial drugs. One specific issue is the lack of a simple, cost-effective, and robust HPLC method to simultaneously determine and quantify the active pharmaceutical ingredients (APIs) in fixed-dose artemether-lumefantrine pharmaceutical dosage forms. The current study developed a novel, simple, sensitive, precise, accurate, and cost-effective RP-HPLC method for the simultaneous determination and quantification of artemether and lumefantrine in pharmaceutical dosage forms. The HPLC analysis was carried out on an Agilent 1260 Infinity Series HPLC system equipped with an ODS Intersil-C8 (150 × 4.6 mm) 5.0 µm column, by isocratic elution. The mobile phase composition consisted of acetonitrile and 0.05% orthophosphoric acid buffer of pH 3.5 in the ratio of 70 : 30 v/v. The analysis was performed at a 1 mL/min flow rate and a column temperature of 25°C. The total run time was 6 minutes. The detection was done with a variable wavelength detector (VWD) at an isosbestic point wavelength (λ) of 210 nm. The developed method was validated according to the ICH guidelines concerning system suitability, specificity, linearity, accuracy, precision, and robustness. The system suitability of the developed method revealed satisfactory theoretical plates and symmetry factors. The method proved to be specific, with no interference of mobile phase or excipients. The calibration plot exhibited linearity over the concentration range of 275–1925 μg/mL with = 0.9992 for artemether and a range of 150–1050 μg/mL with = 0.9985 for lumefantrine. The accuracy of the method, determined by the recovery study, was 99.79–100.16% for artemether and 99.04–99.50% for lumefantrine. The % RSD values for intraday precision were 0.175 and 0.203, while interday precision values were 0.340 and 0.554 for artemether and lumefantrine, respectively. The method demonstrated robustness when subjected to slight modifications in the flow rate, column temperature, and mobile phase composition. The developed analytical method proved satisfactory as per ICH guidelines and hence can be used for the determination and quantification of artemether and lumefantrine in bulk drug and pharmaceutical dosage forms.


  • Open Access

    Physicochemical and Microbiological Characteristics of Stem Bark Exudate Gum of Cordia millenii Tree in Conventional Release Tablets

    by Samuel Lugrie Kipo, Kwabena Ofori-Kwakye, Noble Kuntworbe, Raphael Johnson, Mariam El Boakye-Gyasi, Yaa Asantewaa Osei, Frederick Akuffo Owusu

    The development of a raw material into an acceptable pharmaceutical excipient involves evaluation of the physicochemical and formulation properties of the potential raw material. Results from these evaluations may serve as a guide to subsequent use of the substance. The objective of the study was to evaluate the physicochemical and microbiological properties of the stem bark gum of Cordia millenii tree in conventional release paracetamol tablets. From the physicochemical evaluations, the gum was slightly acidic and soluble in all the aqueous-based solvents, except 0.1N HCl in which it was sparingly soluble. All the absorptive properties of the gum indicated tablet disintegrating potential for tablet formulation. The total ash of the gum was higher than that of the international standard gum arabic. Micromeritic properties of the gum indicated the need for a flow aid to improve its flowability. There were no harmful microorganisms detected in the gum. Aerobic organisms and moulds and yeast were detected within permissible limits. Tablets formulated using six different concentrations of gum dispersions as a binder were generally soft and failed the USP T80 standard of dissolution, indicating poor binding and drug releasing properties. Quality control properties of three different batches of tablets containing varying concentrations of the dry gum as a disintegrating agent were comparable to tablets containing equal concentrations of corn starch. The in vitro drug releases were similar at all-time points of drug evaluation. The gum can therefore be considered as a good disintegrant in the formulation of conventional release tablets.


  • Open Access

    Formulation and Evaluation of Herbal‐Based Antiacne Gel Preparations

    by Julia Afrakoma Ansong, Emmanuel Asante, Raphael Johnson, Mariam El Boakye-Gyasi, Noble Kuntworbe, Frederick William Akuffo Owusu, Kwabena Ofori-Kwakye

    Acne vulgaris is an inflammatory skin condition that affects virtually everyone at some point. Papules, comedones, pustules, scarring, and nodules are standard features of the disease and can have a detrimental social and psychological impact on an individual. Although allopathic acne treatments are available, they have adverse side effects, are expensive, and are prone to cause antibiotic resistance. The present study is aimed at formulating and evaluating topical gels containing Aloe vera, Allium cepa, and Eucalyptus globulus extracts as potential antiacne drugs. Six formulations containing the herbal extracts were prepared using 1% Carbopol 940 as a gelling agent. The phytochemical composition of the plant extracts was determined. The extracts and gels’ minimum inhibitory concentration (MIC) was assessed using the microbroth dilution method. The physicochemical properties of the formulated gels, such as homogeneity, colour, texture, odour, grittiness, spreadability, extrudability, viscosity, pH, and drug content, were evaluated. All the plant extracts contained alkaloids, flavonoids, tannins, triterpenoids, and coumarins. The gel formulations showed varying activity against Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, Candida albicans, and Pseudomonas aeruginosa at various concentrations. The phytochemical components of the plant extracts are probably responsible for the antimicrobial activity of the gel formulations. The 5% Aloe vera‐Allium cepa (1 : 1) combination gel formulation showed excellent activity against Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans, with MICs of 12.50, 25.00, 6.25, 25.00, and 12.50 mg/mL, respectively. The gels generally had good physicochemical and antimicrobial properties and could be used as antiacne remedies.


  • Open Access

    Pharmaceutical Applications of Glucose Syrup from High Quality Cassava Flour in Oral Liquid Formulations

    by Ivan K. Simpson, Frederick W. A. Owusu, Mariam E. Boakye-Gyasi, Philomena Entsie, Marcel T. Bayor, Kwabena Ofori-Kwakye

    Pharmaceutical oral solutions are preparations in which the active ingredients are dissolved in suitable liquid vehicles such as syrups. This study sought to determine the potential of glucose syrup produced from high quality cassava flour (HQCF) as a vehicle or sweetener in the preparation of paracetamol syrup and simple linctus. Four formulations (two paracetamol syrups (B1 and B2) and two simple linctus formulations (A1 and A2)) were prepared using glucose syrup from HQCF as vehicle or sweetener while two controls (B3 and A3) were prepared for each group using sucrose syrup as vehicle or sweetener. Two brands of paracetamol syrup and simple linctus were purchased from retail pharmacies to serve as standards. Physical and organoleptic parameters such as pH, taste and color, microbial load, and drug content of all formulations were determined. All formulations passed the microbial load and drug content tests as specified by the British Pharmacopoeia. The paracetamol syrups were all sweet with characteristic bitter aftertastes except formulation B2 which was sweetened with sucralose. All the simple linctus formulations were sweet except A2 (sweetened with sucralose) which was very sweet. The taste masking capacity of the glucose syrup produced from HQCF matched that of the sucrose syrup in the products formulated. Therefore, glucose syrup from HQCF could be a suitable alternative to sucrose syrup as a vehicle or sweetener in oral liquid formulations and can ultimately reduce the cost of these oral liquid formulations.


  • Open Access

    Evaluation of the binding and disintegrating properties of gum obtained from the stem bark of Cinnamomum zeylanicum

    by Louisa C. Sarkodie, Philomena Entsie, Mariam E. Boakye-Gyasi, Frederick W.A. Owusu, Marcel T. Bayor, Kwabena Ofori-Kwakye

    Excipients are the various ingredients, apart from the active pharmaceutical ingredients, which are added to pharmaceutical formulations. Excipients obtained from natural sources are preferred over those from synthetic sources because they are cheap, biocompatible and readily available. Gums are made up of carbohydrate units which are linked by glycosidic bonds. This study was aimed at evaluating the potential binding and disintegrating properties of gum obtained from the bark of Cinnamomum zeylanicum, which was obtained from Effiduase in the Ashanti region of Ghana. The gum was extracted using 96% ethanol and the moisture content, Fourier transform infrared spectroscopy spectra, water holding capacity, swelling index and flow properties of the gum were determined. The gum was used to formulate tablets at different concentrations (10% w/v, 15% w/v and 20% w/v) as binder with acacia as the standard. The gum was also used to formulate tablets at different concentrations (5% w/v, 7.5% w/v and 10% w/v) as disintegrant with starch as the standard. Quality control tests were then conducted on all formulated tablets. The gum exhibited good flow and physicochemical properties. All formulated tablets passed the uniformity of weight test, friability test, disintegration test, hardness test, uniformity of dimensions test and drug content. All batches of tablets, except Batch 7, passed the dissolution test. Based on the study carried out, C. zeylanicum gum can be used as an alternative excipient to acacia and starch as a binder and a disintegrant, respectively. Significance: A natural polysaccharide (gum) from the bark of Cinnamomum zeylanicum tree can be harnessed and commodified as a pharmaceutical excipient (binder and disintegrant) in the production of immediate release tablets.


  • Open Access

    Potential and Comparative Tablet Disintegrant Properties of Pectin Obtained from Five Okra Genotypes in Ghana

    by Frederick William Akuffo Owusu, Mariam El Boakye-Gyasi, Jacob Kwaku Agbenorhevi, Marcel Tunkumgnen Bayor, Kwabena Ofori-Kwakye

    Okra pectin has been studied as a potential excipient in tablet formulations for pharmaceutical industries. Okra is widely grown and available in Ghana and other parts of the world. The prospective use of pectin from okra genotypes grown in Ghana as tablet disintegrants has not been reported. This study aims to determine the potential and comparative disintegrating properties of pectin from five okra genotypes (Abelmoschus esculentus L.) in Ghana using uncoated immediate release paracetamol tablet formulations. The yield of the pectin from the various genotypes ranged between 6.12 and 18.84% w/w. The extracted pectins had pH ranging from slightly acidic to almost neutral (6.39–6.92). Pectin from the various genotypes exhibited good swelling indexes (˃200%), varying solubility in different solvents, and low moisture content (˂20%). Elemental analysis of the extracted pectin from the various genotypes revealed very low levels of toxic metals and micronutrients. Pectin from the various genotypes was evaluated as disintegrants within concentrations of 5–10% w/w (F1–F18). Their disintegrating properties were compared to that of maize starch BP. All the formulated batches of uncoated immediate release paracetamol tablets (F1–F18) passed the following: uniformity of weight test, uniformity of dimensions, hardness, friability (˂1%), and drug content (95–105%). Significant differences ( ) were observed between the hardness of the maize starch tablets and tablets formulated from pectin of the various genotypes. Pectin from all genotypes other than PC5 exhibited good disintegrating properties (DT ˂ 15 min) and subsequently passed the dissolution profile test (≥70% release in 45 minutes). Tablets formulated with PC5 as disintegrants at all concentrations (5% w/w (F5), 7.5% w/w (F11), and 10% w/w (F17)) failed the disintegration and dissolution tests. Ultimately, pectins extracted from PC1, PC2, PC3, and PC4 can be commercially exploited as disintegrants in immediate release tablets.


  • Open Access

    Utilization of Pectin from Okra as Binding Agent in Immediate Release Tablets

    by Frederick W. A. Owusu, Mariam E. Boakye-Gyasi, Philomena Entsie, Marcel T. Bayor, Kwabena Ofori-Kwakye

    Polymeric materials from plants continue to be of interest to pharmaceutical scientists as potential binders in immediate release tablets due to availability, sustainability, and constant supply to feed local pharmaceutical industries. Paracetamol tablet formulations were utilized in investigating the potential binding characteristics of pectin harnessed from various okra genotypes (PC1‐PC5) in Ghana. The pectin yields from the different genotypes ranged from 6.12 to 18.84%w/w. The pH of extracted pectin ranged from 6.39 to 6.92, and it had good swelling indices and a low moisture content. Pectin extracted from all genotypes were evaluated as binders (10, 15, and 20%w/v) and compared to tragacanth BP. All formulated tablets (F1‐F18) passed the weight uniformity, drug content, hardness, and friability tests. Based on their crushing strength, tablets prepared with pectin from the various genotypes were relatively harder (P ≤ 0.05) than tablets prepared with tragacanth BP. Tablets prepared with pectins as binders at 10%w/v and 15%w/v passed the disintegration and dissolution tests with the exception of PC4 at 15%w/v. Incorporation of pectin from all genotypes (excluding PC5) as a binder at concentrations above 15%w/v (F13, F16, F14, and F15) produced tablets which failed the disintegration test and showed poor dissolution profiles. Thus, pectin from these genotypes can be industrially commodified as binders in immediate release tablets using varying concentrations.


  • Open Access

    Formulation and evaluation of sustained release matrix tablets of capparis erythrocarpos roots extract to improve patient compliance in management of arthritis

    by Frederick W.A. Owusu, Mariam E. Boakye-Gyasi, Priscilla K. Mante, Edmund Ekuadzi, Kwabena Ofori-Kwakye, Eric Woode